| 1. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 2. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 3. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 4. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 5. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t (refereegranskat)
|
|
| 6. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 7. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 8. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 9. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 10. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 11. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 12. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 13. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 14. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 15. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 16. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 17. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 18. |
- Aad, G., et al.
(författare)
-
- 2012
-
Tidskriftsartikel (refereegranskat)
|
|
| 19. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 20. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 21. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 22. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 23. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 24. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 25. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 26. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 27. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 28. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 29. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t
|
|
| 30. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 31. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 32. |
|
|
| 33. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 34. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 35. |
- Abdesselam, A., et al.
(författare)
-
Engineering for the ATLAS SemiConductor Tracker (SCT) end-cap
- 2008
-
Ingår i: Journal of Instrumentation. - 1748-0221. ; 3
-
Tidskriftsartikel (refereegranskat)abstract
- The ATLAS SemiConductor Tracker (SCT) is a silicon-strip tracking detector which forms part of the ATLAS inner detector. The SCT is designed to track charged particles produced in proton-proton collisions at the Large Hadron Collider (LHC) at CERN at an energy of 14 TeV. The tracker is made up of a central barrel and two identical end-caps. The barrel contains 2112 silicon modules, while each end-cap contains 988 modules. The overall tracking performance depends not only on the intrinsic measurement precision of the modules but also on the characteristics of the whole assembly, in particular, the stability and the total material budget. This paper describes the engineering design and construction of the SCT end-caps, which are required to support mechanically the silicon modules, supply services to them and provide a suitable environment within the inner detector. Critical engineering choices are highlighted and innovative solutions are presented - these will be of interest to other builders of large-scale tracking detectors. The SCT end-caps will be fully connected at the start of 2008. Further commissioning will continue, to be ready for proton-proton collision data in 2008.
|
|
| 36. |
|
|
| 37. |
- van Bragt, JJMH, et al.
(författare)
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
- 2020
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 55:1
-
Tidskriftsartikel (refereegranskat)abstract
- Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
|
|
